Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males

Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men

(2015) Ali Asmar et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

GLP-1 Receptor Agonist Exenatide Increases Capillary Perfusion Independent of Nitric Oxide in Healthy Overweight Men

(2015) M. M. Smits et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial

(2015) Juris J. Meier et al.   DIABETES CARE

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

(2015) Xavier Pi-Sunyer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

(2015) Marc A. Pfeffer et al.   NEW ENGLAND JOURNAL OF MEDICINE

GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody

(2014) Charles Pyke et al.   ENDOCRINOLOGY

Effects of Exogenous Glucagon-Like Peptide-1 on the Blood Pressure, Heart Rate, Mesenteric Blood Flow, and Glycemic Responses to Intraduodenal Glucose in Healthy Older Subjects

(2014) Laurence G. Trahair et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Combining incretin-based drugs and RAAS inhibitors: more cons than pros?

(2014) Lennart Tonneijck et al.   Lancet Diabetes & Endocrinology

Effects of induced hyperinsulinaemia with and without hyperglycaemia on measures of cardiac vagal control

(2013) M. Berkelaar et al.   DIABETOLOGIA

Insulin- and glucagon-like peptide-1-induced changes in heart rate and vagosympathetic activity: why they matter

(2013) P. Valensi et al.   DIABETOLOGIA

The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?

(2013) Marcel H. A. Muskiet et al.   Nature Reviews Nephrology

Direct cardiovascular effects of glucagon like peptide-1

(2013) Asfandyar Sheikh   Diabetology & Metabolic Syndrome

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis

(2013) Louise E Robinson et al.   BMJ Open

Investigation of the haemodynamic effects of exenatide in healthy male subjects

(2012) Buddhike Mendis et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

(2012) Juris J. Meier   Nature Reviews Endocrinology

Resting heart rate is associated with cardiovascular and all-cause mortality after adjusting for inflammatory markers: The Copenhagen City Heart Study

(2011) Magnus T Jensen et al.   European Journal of Preventive Cardiology

Pulse contour cardiac output derived from non-invasive arterial pressure in cardiovascular disease

(2010) L. W. J. Bogert et al.   ANAESTHESIA

Nexfin Noninvasive Continuous Blood Pressure Validated Against Riva-Rocci/Korotkoff

(2009) Daan W. Eeftinck Schattenkerk et al.   AMERICAN JOURNAL OF HYPERTENSION

Higher arterial stiffness, greater peripheral vascular resistance and lower blood flow in lower-leg arteries are associated with long-term hyperglycaemia in type 2 diabetic patients with normal ankle-brachial index

(2009) Eiji Suzuki et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans

(2008) Adil E. Bharucha et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY